Preclinical studies on animal models demonstrated that therapy involving simultaneous blockade of TIM-3 and PD-1 pathways improved anti-tumour response and effectively suppressed tumour growth, compared to when only one pathway was targeted (Andrews et al. 2019; Curigliano et al. 2021). This evidence concerns the gene HAVCR2 and neoplasm.